Triamcinolone Acetonide Hydrofluoroalkane Inhalation - Aventis: Azmacort HFA, Azmacort HFA-134a, RG 5016, Triamcinolone Acetonide HFA inhalation - Aventis

Author:  

Publisher: Adis International

ISSN: 1174-5886

Source: Drugs in R&D, Vol.3, Iss.2, 2002-02, pp. : 141-142

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Adis CommentsAzmacort HFA [RG 5016] is a non-chlorofluorocarbon (CFC) inhalation formulation of the off-patent corticosteroid, triamcinolone acetonide, developed by Aventis Pharma using hydrofluoroalkane (HFA-134a) propellant. It is indicated for the preventative management of asthma. The 75mug formulation and the high-potency 225mug formulation were deemed approvable by the US FDA in March 1998 and April 1999, respectively. Both formulations are in phase III clinical trials in Europe. In December 2001, Aventis formed an agreement with ViroPharma regarding the co-promotion of triamcinolone acetonide in the USA.